Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity

Helen M. Sheldrake, Sandra Travica, Inger Johansson, Paul M. Loadman, Mark Sutherland, Lina Elsalem, Nicola Illingworth, Alexander J. Cresswell, Tristan Reuillon, Steven D. Shnyder, Souren Mkrtchian, Mark Searcey, Magnus Ingelman-Sundberg, Laurence H. Patterson, Klaus Pors

Research output: Contribution to journalArticlepeer-review

26 Citations (SciVal)

Fingerprint

Dive into the research topics of 'Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds